Pulmonary arterial hypertension in adults with congenital heart disease: markers of disease severity, management of advanced heart failure and transplantation.
Katrijn JansenAndrew ConstantineRobin CondliffeRobert TullohPaul CliftShahin MoledinaS John WortKonstantinos DimopoulosPublished in: Expert review of cardiovascular therapy (2021)
All patients with PAH-CHD should be followed up in expert centers, where they can receive appropriate risk assessment, PAH therapy, and supportive care. Referral for transplant assessment should be considered if there continue to be clinical high-risk features, persistent symptoms, or acute heart failure decompensation despite appropriate PAH specific therapy. Expert management of PAH-CHD patients, therefore, requires vigilance for these features, along with a close relationship with local advanced heart failure services and a working knowledge of listing criteria, which may disadvantage congenital heart disease patients.
Keyphrases
- heart failure
- pulmonary arterial hypertension
- end stage renal disease
- acute heart failure
- healthcare
- risk assessment
- congenital heart disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- primary care
- prognostic factors
- peritoneal dialysis
- palliative care
- pulmonary hypertension
- pulmonary artery
- left ventricular
- mental health
- depressive symptoms
- cell therapy
- pain management
- mesenchymal stem cells